Nuclear-Medicine Physician's Notes · Lu-177 n.c.a.

One Lu-177 import line, three downstream theranostic clinics.

DOTATATE for NETs, PSMA-617 for prostate, FAPI for tumour-stroma — three protocols, three ethics committees, three downstream patient pathways. But upstream of the labelling bench the supply chain is one: the same n.c.a. Lu-177 starting material lands on therapy day, in the same vial geometry, with one regulatory dossier. This post draws what shares and what doesn't.

The three clinics side by side

Different indications, same starting material

¹⁷⁷Lu-DOTATATE — PRRT clinic

Indication: SSTR2+ gastroenteropancreatic and bronchopulmonary NETs (GEP-NETs, atypical carcinoids).
Protocol: 7.4 GBq per cycle × 4 cycles, 8-week intervals.
At the bench: DOTATATE peptide labelled to ¹⁷⁷LuCl₃ at standard radiopharmacy conditions; ≥98 % radiochemical purity at release.
Theranostic pairing: Ga-68 DOTATATE PET/CT for SSTR2 imaging and cycle response.
Evidence base: NETTER-1 and NETTER-2 trials; standard-of-care in EANM and ESMO guidance.

¹⁷⁷Lu-PSMA-617 — prostate clinic

Indication: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), post-AR-targeted-therapy and post-taxane.
Protocol: 7.4 GBq per cycle, up to 6 cycles, 6-week intervals.
At the bench: PSMA-617 (vipivotide tetraxetan) labelled to ¹⁷⁷LuCl₃; ≥98 % radiochemical purity at release.
Theranostic pairing: Ga-68 PSMA-11 or F-18 PSMA-1007 PET/CT for PSMA expression and response.
Evidence base: VISION trial (Sartor et al. 2021) — FDA/EMA-approved indication; established in NCCN and ESMO.

¹⁷⁷Lu-FAPI — tumour-stroma clinic

Indication: FAP-positive solid tumours — pancreatic adenocarcinoma, soft-tissue sarcoma, breast / colorectal subsets, currently investigational.
Protocol: Per-protocol dosing; ongoing dose-escalation and dosimetry studies (no single standard cycle yet).
At the bench: FAPI-46 / FAPI-04 labelled to ¹⁷⁷LuCl₃ under research-pharmacy conditions; per-protocol QC.
Theranostic pairing: Ga-68 FAPI or F-18 FAPI PET/CT for FAP expression imaging.
Evidence base: Heidelberg group early-phase data; multi-centre pilot dosimetry studies; not yet a regulatory-approved indication.

What the supply chain shares

Five upstream elements that don't split by indication

One Lu-177 import licence covers all three clinical programmes — the AERB Lu-177 import path does not split by labelling target. Saxsons supplies one consignment per calibration date.
One cold-chain delivery window. Calibration at a defined date / time so the radiopharmacy can sequence DOTATATE, PSMA-617 and (where on protocol) FAPI labelling within the same therapy-day shift.
One radionuclidic-purity dossier. The Lu-177 Certificate of Analysis and Lu-177m / radionuclidic-impurity report cover all downstream uses — no need to re-qualify per target.
One dosimetry pipeline. Post-therapy ¹⁷⁷Lu SPECT/CT at 208 keV gamma, EANM / AAPM TG-181 / TG-211 workflow, regardless of which peptide carried the activity.
Three separate ethics / regulatory dossiers downstream. AERB licensing covers the radionuclide; CDSCO + hospital ethics committee approvals are per clinical indication (DOTATATE is a globally registered standard-of-care; PSMA-617 is approved abroad and rolling into Indian practice; FAPI is investigational).

Three traps to plan for

A shared supply chain ≠ a shared SOP

Sharing the supply chain does NOT mean sharing release criteria. Each labelled product has its own radiochemical purity, sterility and endotoxin release tests — the radiopharmacy SOP has to cover each peptide separately.
High specific activity reduces the peptide mass needed for a fixed activity. Inheriting an SOP from a carrier-added Lu-177 era (more peptide for the same GBq) over-doses the peptide if not re-titrated.
FAPI clinical use without an approved indication requires hospital ethics committee approval, CDSCO investigational-use coverage, and patient-level informed-consent appropriate for off-protocol or trial use. Don't treat FAPI labelling as a routine extension of an approved PRRT line.

Lu-177 n.c.a.

More for this product

Sibling posts in the Lu-177 n.c.a. family.

For Nuclear-Medicine Physician

Nuclear-Medicine Physician

Why the specs define n.c.a.

Specific activity ≥ 3,000 GBq/mg, radionuclidic purity ≥ 99.9 %, radiochemical purity ≥ 99 % — the three numbers that separate genuine n.c.a. from carrier-added Lu-177 marketed as n.c.a., and what changes in the patient when any one is missed.

Read this